Date: 3/19/2025
DATE & TIME (Pacific Time):
Day 1: March 24th, 2025 | 2:00 pm – 6:50 pm ET
Day 2: March 25th, 2025 | 7:30 am – 2:30 pm ET
Date: 6/04/2024
DATE & TIME (Pacific Time):
Day 1: Thursday, June 6, 2024, from 3:00 pm - 6:00 pm (7:00 pm - 9:00 pm Reception dinner, TBD)
Day 2: Friday, June 7, 2024, from 8:00 am - 4:00 pm
Date: 3/20/2024
The Advanced Research Projects Agency for Health (ARPA-H) announced the ADvanced Analysis for Precision cancer Therapy (ADAPT) program. The ADAPT program seeks to develop an adaptive cancer treatment platform that detects tumor changes, recommends treatment plan updates, and evaluates revised plans through a novel clinical trial design. The program aims to improve survival for patients with metastatic cancer by continuously matching each patient's evolving cancer with the best available therapy.
The module announcement outlines three technical areas for proposals: developing predictive biomarkers (TA1), designing an evolutionary clinical trial (TA2), and implementing an adaptive treatment platform (TA3). Proposals are due by May 6, 2024 and will be evaluated based on several criteria including scientific and technical merit, management approach, and equity and accessibility plans for clinical trials. Awards will support groundbreaking research to develop new strategies for treating cancer evolution through high-impact biomedical approaches.
Date: 3/11/2024
Registration is now open for the Stromal Mutations: Cause & Consequence in Cancer Biology Workshop, to be held on May 2-3, 2024. The registration link (along with more details on the agenda) can be found here:
https://event.roseliassociates.com/nci-dcb-stromal-mutations-ws-2024/
This Workshop is open to all who wish to attend and will be co-chaired by Drs. Edna Cukierman (Fox Chase) and Kai Kessenbrock (UC-Irvine). The goal is to have a much-needed and timely discussion on the significance of stromal mutations at different stages of tumor evolution – from initiation to metastasis and treatment resistance. Research in this area lags severely behind that of traditional cancer cell mutations. Notably, strategies on characterizing the stromal elements – within the mutation-signaling continuum – that are contributing to these various stages of tumorigenesis remain understudied, despite published (yet historical and anecdotal) evidence in support of this notion. Studies on “stromal effects” are often limited to measuring and/or testing for short term/acute biological and biochemical reprogramming and remodeling events linked to stromal cell state(s), stromal landscape/fibrosis, and immune/inflammatory responses.
Missing from the analyses (and an emphasis of this Workshop) is the longer-term implications and ramifications of stromal cell mutational status – be it somatic or germline and/or nuclear or mitochondrial. With the recent advances in single-cell technologies, multiparameter imaging, and ability to integrate multi-omics with spatial TME context, the cancer research field is now well positioned to interrogate and detect stroma cell mutation(s) as an added – but missing – layer of cancer predispositions, and dynamic complexities throughout its growth and progression.
Please feel free to send the link to anyone who might be interested in the workshop!
Date: 2/07/2024
The Division of Cancer Biology (DCB) at the NCI announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects under NOT-CA-24-029. The due date is April 12, 2024.
DCB led or co-led programs appropriate for this opportunity include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Epstein Barr Virus Associated Lymphoma Consortium (EALC), the Metabolic Dysregulation and Cancer Risk Program (MeDoC), the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Pediatric Immunotherapy Network (PIN), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Let us know if you have any questions.
Date: 1/23/2024
Please find below information announcing the 2024 Cancer Moonshot Seminar Series. The presentations will showcase research from different Cancer Moonshot initiatives that support the 10 recommendations of the Blue Ribbon Panel report. These presentations will inform the community about the progress of Cancer Moonshot-funded projects, provide outreach related to Cancer Moonshot projects, enhance discussions and collaborations related to Cancer Moonshot research, and promote the sharing of data from Cancer Moonshot initiatives. Several of the seminars will feature junior investigators presenting their Cancer Moonshot research projects.
Please register in advance https://events.cancer.gov/cm/seminarseries/registration
If you have questions about the Cancer Moonshot Seminar Series or if you need to request reasonable accommodations to participate in these events, please contact CMSS@mail.nih.gov.
Date: 12/19/2023
Please save the date for Dr. Nastaran Zahir's webinar on February 23rd, 2024 (our February PSRC Monthly SC meeting). Dr. Zahir is the Branch Director for the NCIs Cancer Training Grant.
Given that Dr. Zahir will be touching upon a topic that many are interested in, it would be great if all the PIs in PSRC (well in advance of the February meeting) would consider extending the invitation broadly to senior and junior faculty, post-docs, students, etc involved with the Consortium. This is a rare and unique opportunity for all to learn from and engage directly with the “training experts” at the NCI – and Dr. Zahir is THE EXPERT of them all!
Her contact info and Bio are as follows:
Nastaran (Nas) Zahir, PhDhttps://www.cancer.gov/grants-training/training/contact/nastaran-zahir
Date: 12/15/2023
The National Cancer Institute (NCI) has released a new Request for Information (RFI): Inviting Comments and Suggestions on the National Cancer Institute’s Support of Early Career, Mentored Cancer Researchers and Trainees. NCI is committed to supporting the training and development of the next generation of the cancer research workforce. We are seeking input on potential approaches and innovations within NCI's purview based on community feedback.
We invite suggestions and comments on current or potentially new funding mechanisms to support early career, mentored cancer researchers from middle school, high school, undergraduate and graduate studies through early research independence. NCI is interested in understanding how these mechanisms are structured and positioned to meet the needs of a diverse cancer research workforce. Your feedback on this matter would be greatly appreciated. Responses are due by December 29, 2023.
For questions, please contact nci_earlycareer_rfi@mail.nih.gov.